Table 3.

Significant clinical and laboratory data from COVID-19 inpatients on admission associated with APLA positivity.

APLA	Parameter	N 1	APLA Negative	APLA Positive	p-Value	Adjusted p-Value
aCL IgM	Thrombotic history †	92	1; 1.2% [0, 6.8]	2; 16.7% [2.1, 48.4]	0.044	0.046
aPS IgM	COVID-19-related thrombosis †	92	5; 5.8% [1.9, 13]	2; 40% [5.3, 85.3]	0.046	0.050
aPI IgM	IL-6 ††	72	27.5 [10.6, 63.5]	150 [88.2, 335]	0.007	0.012
aPI IgM	ferritin ††	82	472 [259, 810]	1657 [630, 2366]	0.034	0.041
aPE IgG	INR ††	78	1.1 [1.0, 1.2]	1.4 [1.35, 1.45]	0.041	0.043

Only those APLAs with a significant association with a clinical or laboratory parameter are presented. † For categorical variables (thrombotic history and COVID-19-related thrombosis), it shows the number of people presenting the clinical parameter distributed in whether they were positive or negative for the indicated APLA; percentage results from dividing it by the number of people testing positive or negative for that aPL according to Table 2 (n; % [95% CI], Fisher’s exact test). †† For numerical variables (IL-6, ferritin, and PT), it shows the median value and IQR of that clinical parameter for those patients who tested positive or negative for the indicated APLA (median [IQR] and Mann–Whitney U test). ¹ The n column indicates the total number of patients who were analysed for the indicated clinical parameter. IL-6, interleukin-6; INR, international normalised ratio.